Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Utility scores

From: Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

Parameters

Utility

Time with Disease

Ranges

References

Screening Pap

0.98

1 months

2 weeks – 2 months

Myers et al39 and Insinga et al40

ASCUS pap

0.94

1 month

2 weeks-2 months

 

>= LSIL pap

0.91

2 months

1–4 months

 

Warts

0.91

2 months

1–4 months

 

CIN 1

0.91 0.96

2 months 10 months

2–4 months 0–10 months

 

CIN 2–3

0.87

2 months

1–4 months

 

FIGO I

0.76

5 years

1–5 years

 

FIGO II

0.67

5 years

1–5 years

 

FIGO III

0.67

5 years

1–5 years

 

FIGO IV

0.67

5 years

1–5 years

 
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us